Hodgkin's lymphoma with HLH and complete remission with brentuximab-based therapy

Blaine Knox, Daulath Singh, Hanh Mai, Kamran Mirza

Research output: Contribution to journalArticlepeer-review

2 Scopus citations


A 63-year-old man presented to the hospital with generalised weakness, fatigue and a 22 kg weight loss 4 months after being diagnosed with sarcoidosis on a mediastinal lymph node biopsy, with minimal improvement in symptoms on prednisone and methotrexate therapy. On arrival, he was found to have a haemoglobin of 57 g/L and platelet count of 82×10 9/L. Further work-up revealed six of eight diagnostic criteria for haemophagocytic lymphohistiocytosis (HLH): fever >38.9°C, splenomegaly, cytopaenia, hypertriglyceridaemia, haemophagocytosis and elevated ferritin >31 000 ng/mL. He was also found to have Epstein-Barr viraemia with greater than 17 000 copies. Bone marrow biopsy showed the presence of haemophagocytic histiocytes and evidence of classic Hodgkin's lymphoma. He was started on HLH-94 protocol. Later treatment was switched to lymphoma-directed therapy and he finished six cycles of A+AVD (brentuximab vedotin, doxorubicin, vinblastine and dacarbazine) with end-of-treatment positron emission tomography/CT and bone marrow negative for lymphoma.

Original languageEnglish (US)
Article numbere231629
JournalBMJ Case Reports
Issue number12
StatePublished - Dec 8 2019


  • haematology (drugs and medicines)
  • haematology (incl blood transfusion)

ASJC Scopus subject areas

  • Medicine(all)


Dive into the research topics of 'Hodgkin's lymphoma with HLH and complete remission with brentuximab-based therapy'. Together they form a unique fingerprint.

Cite this